Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate
Open Access
- 17 January 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (4) , 996-999
Abstract
Objectives: Objective measurement of antiretrovirals may aid clinical interventions for improving adherence to HIV prevention or treatment regimens. A point-of-care urine test could provide real-time information about recent adherence to regimens containing tenofovir disoproxil fumarate or tenofovir alafenamide. We developed a lateral flow immunoassay (LFA) and ELISA for urinary tenofovir. Methods: The intensity of the LFA test line was quantified using an optical reader and visually scored 0–5 by two independent people, using a reference card. The sensitivity and specificity of both the ELISA and LFA were determined for two different tenofovir concentration cut-offs for tenofovir disoproxil fumarate and tenofovir alafenamide adherence—1500 and 150 ng/mL, respectively. To validate the assays, we measured 586 urine samples from 28 individuals collected as part of a study of tenofovir pharmacokinetics in adults, which were also measured by MS for reference. Results: Both the LFA signal and ELISA signal were each strongly correlated with drug concentrations (0.91 and 0.92, respectively). The LFA signal and ELISA were highly sensitive and specific at both thresholds (LFA sensitivity/specificity: tenofovir disoproxil fumarate, 89%/96%; and tenofovir alafenamide, 90%/96%) (ELISA sensitivity/specificity: tenofovir disoproxil fumarate, 94%/94%; and tenofovir alafenamide, 92%/84%). Visual scoring of the LFA was also highly sensitive and specific at both the tenofovir disoproxil fumarate threshold and the tenofovir alafenamide threshold (sensitivity/specificity: tenofovir disoproxil fumarate, 91%/94%; and tenofovir alafenamide, 87%/90%). Conclusions: Our rapid semi-quantitative test can measure tenofovir concentrations relevant to both tenofovir alafenamide and tenofovir disoproxil fumarate adherence, which may support adherence-promoting interventions across a range of HIV care settings.Keywords
All Related Versions
Funding Information
- National Institutes of Health
- NIAID (R01AI13664)
This publication has 15 references indexed in Scilit:
- Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study)Clinical Infectious Diseases, 2020
- Using Real-Time Adherence Feedback to Enhance Communication About Adherence to Antiretroviral Therapy: Patient and Clinician PerspectivesJournal of the Association of Nurses in AIDS Care, 2020
- Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care TestJAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
- Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus InfectionsClinical Infectious Diseases, 2018
- A competitive lateral flow assay for the detection of tenofovirAnalytica Chimica Acta, 2018
- Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time MonitoringCurrent HIV/AIDS Reports, 2018
- A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET studyBMC Infectious Diseases, 2017
- Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Physician Estimate of Antiretroviral Adherence in India: Poor Correlation with Patient Self-Report and Viral LoadAIDS Patient Care and STDs, 2010
- The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus–Infected Persons in Clinical TrialsClinical Infectious Diseases, 2002